On this page
- What oncology billing involves
- Who this affects
- Chemotherapy administration and infusion coding
- Hierarchy and time rules
- Nursing documentation drives the claim
- Drug billing: J-codes, units, and NDC
- JW and JZ modifiers for discarded drug
- Buy and bill versus specialty pharmacy
- Prior authorization in oncology
- Clinical trial billing
- Radiation oncology basics
- Common causes of oncology denials
- Investigation and correction workflow
- Hypothetical example: discarded drug and units
- How Mednex works with oncology practices
- Mednex and practice responsibilities
- Records and access needed
- Quality checks and exceptions
- How progress is measured
- What cannot be promised
- Next steps
What oncology billing involves
An oncology visit rarely produces one charge. A patient on a typical infusion day may have an office visit, lab draw, premedication, an antiemetic, the chemotherapy drug itself, one or more administration services, and hydration. Each piece has its own code, units, documentation requirement, and payer edit. The billing team has to connect the order, the pharmacy or inventory record, the nursing infusion record, and the authorization before a clean claim exists.
Five areas drive the work:
- Evaluation and management. New and established patient visits, often on the same day as treatment, which calls for modifier 25 when the visit is significant and separately identifiable.
- Administration of treatment. Chemotherapy and other complex biologic administration codes, therapeutic infusion and injection codes, and hydration, all governed by time and by a hierarchy.
- Drugs and biologics. HCPCS J-codes and related codes, billing units, NDC reporting, and discarded-drug modifiers.
- Authorization and coverage. Regimen-level approvals, off-label use, payer pathway programs, and specialty pharmacy rules.
- Special programs. Clinical trials, radiation oncology, imaging, and chronic or supportive care services.
The general claim workflow is covered on the medical billing page. This page covers what changes in oncology.
Who this affects
- Medical oncology and hematology groups that stock and administer drugs in the office
- Practices that buy drugs from distributors and carry significant inventory cost
- Groups affected by payer rules that route drugs through specialty pharmacy
- Radiation oncology practices, freestanding or hospital-based
- Practices participating in clinical trials with industry or cooperative group sponsors
- Hospital-affiliated practices where facility and professional billing must stay separate
- Practices considering outsourcing versus in-house billing because drug claim errors are costly
Chemotherapy administration and infusion coding
Administration is reported separately from the drug. The CPT code families most oncology offices use include:
| Service type | Typical code family | What the record must show |
|---|---|---|
| Chemotherapy IV infusion | 96413 for the first hour, 96415 for each additional hour, 96417 for each additional sequential infusion of a different drug | Start and stop time, drug, access site, and the initial service designation |
| Chemotherapy IV push | 96409 for the first drug, 96411 for each additional drug | Drug, time, and whether it is a push or an infusion |
| Chemotherapy injection, subcutaneous or intramuscular | 96401 for non-hormonal antineoplastics, 96402 for hormonal | Drug, route, site, and dose |
| Therapeutic or prophylactic infusion and push | 96365 to 96379 family | Medical necessity, start and stop time, and a separate access when billed with chemo |
| Hydration | 96360 and 96361 | Separate documented need and time beyond a threshold |
Check each code in the current CPT book before billing, as descriptions and rules are updated.
Hierarchy and time rules
CPT sets a hierarchy for services in a non-facility setting: the initial service is the one that best describes the key reason for the encounter, and chemotherapy administration outranks therapeutic and hydration services. Other services in the visit are reported as add-on or sequential codes. Time rules are strict. An infusion must run longer than 15 minutes to be reported as an initial hour, and an additional hour requires more than 30 minutes beyond the first hour. Concurrent infusions of different drugs through the same line are generally not separate services. A short push into an existing infusion is a sequential or concurrent service under CPT rules, not a new initial service.
Hospital outpatient departments follow different payment methods, and facility claims have their own coding guidance. A practice that is hospital-owned or provider-based should confirm which claim form and rules apply to each service.
Nursing documentation drives the claim
Most administration denials trace back to the infusion record. Billing needs the following from nursing: patient identification, order reference, drug name, dose, lot and NDC if tracked, route and site, start and stop times for each infusion or push, vascular access details, and any interruptions or reactions. Estimated times, or a chart where start and stop are copied from the order, will not hold up in review. The practice should decide who owns the infusion record and how late entries are marked.
Drug billing: J-codes, units, and NDC
Most injectable and infused cancer drugs are reported with HCPCS J-codes, with C-codes, Q-codes, or not-otherwise-classified codes in some cases. See the J-codes guide for the basic logic. Three details cause the most losses.
- Billing units. Each code defines a billing unit, such as a number of milligrams. The vial or dose is measured in different units, so the biller must convert correctly. A dose in milligrams and a code defined per 10 milligrams give a different unit count. Errors here pay the wrong amount, not just a denial.
- Code selection. Brand, generic, and biosimilar products can have separate codes. New products often start with a temporary or unclassified code, then move to a permanent one. Using a retired code, or an unclassified code when a specific one exists, leads to denial.
- NDC reporting. Many Medicaid programs and some commercial payers require the National Drug Code on drug lines, reported in an 11 digit format with a unit of measure and quantity. Others do not. A wrong package size or an NDC that does not map to the billed J-code will cause rejections. Verify each payer’s requirement.
Payment for drugs billed under Medicare Part B is tied to a published sales price methodology that is updated quarterly, and many commercial contracts reference the same or a similar benchmark. Practices should track the allowed amount against their acquisition cost for high-volume drugs. When allowed amounts fall below what the practice paid the distributor, the issue is a contract and purchasing problem, not a billing error, but billing data is how it gets noticed.
JW and JZ modifiers for discarded drug
CMS requires discarded drug modifiers on Medicare Part B claims for separately payable drugs and biologicals supplied in single-dose containers or single-use packages. The CMS JW modifier FAQ states these basics:
- JW reports the amount of drug discarded from a single-dose container. JZ reports that there was no discarded amount.
- JW has been required since 2017. JZ was required for claims starting July 1, 2023, and claims lacking the right modifier may be returned as unprocessable.
- Multiple-dose container drugs are excluded.
- Payment covers the administered dose plus the discarded amount, up to the amount in the labeled container. Claims are split into two lines: the administered units with no modifier, and the discarded units with JW. If nothing is discarded, the full units go on one line with JZ.
- Discarded amounts must be documented in the patient’s record, and CMS does not prescribe the format. Purchasing and inventory records must also be kept.
- Overfill is not payable and JW must not be used for it.
Other payers may have their own versions of these rules or may not apply them. Medicaid and commercial policies differ, and the settings listed as exceptions by CMS, such as certain clinic types and inpatient stays, are not handled the same way.
The modifier is added at billing, but the information comes from the pharmacy or nursing record. If the chart records only the dose given and not the vial size or the amount discarded, billing has to guess. The fix is a field in the infusion record that captures container size and discarded amount for every single-dose drug.
Buy and bill versus specialty pharmacy
Under buy and bill, the practice purchases the drug, stores it, administers it, and bills the payer for the drug and the administration. Under specialty pharmacy arrangements, the payer requires or prefers that a pharmacy supplies the drug for the patient. Common variations are often called white bagging, where the pharmacy ships the drug to the practice for a specific patient, and brown bagging, where the patient receives it and brings it. Payer policies on these approaches vary, and some states restrict them.
| Question | Buy and bill | Specialty pharmacy supply |
|---|---|---|
| Who buys the drug | Practice | Pharmacy, then dispensed for the patient |
| What the practice bills | Drug plus administration | Administration only, with the drug billed by the pharmacy |
| Cash flow risk | Practice carries inventory and payment delay | Practice avoids inventory but may lose drug margin |
| Main denial risks | Units, codes, authorization, JW or JZ, NDC | Drug not delivered in time, wrong patient assignment, administration denied if the drug source is not recorded |
| Waste and replacement | Practice absorbs loss unless billable | Rules on lost or unused doses vary by pharmacy contract |
The billing team should know, per payer and per drug, which pathway applies, because the claim differs. An administration claim for a drug supplied by a pharmacy may need a specific modifier or a drug source statement, depending on the payer. If the payer expects specialty supply and the practice bills the drug anyway, the drug line is denied and the administration line may follow.
Prior authorization in oncology
Authorization in oncology is regimen-based. A request often covers the drug, the dose schedule, the number of cycles, the diagnosis and stage, and sometimes supporting items such as supportive medications, imaging, and lab monitoring. Common friction points:
- Regimen changes. A dose adjustment, drug swap, or added agent mid-course may need a new or amended request.
- Off-label use. Many payers accept use supported by recognized compendia or published evidence, but they require citations and a medical necessity explanation.
- Payer pathway programs. Some payers use oncology pathway or reference programs and may require that a preferred regimen be used or that a reason for a different regimen be given.
- Expiry and cycle counts. Approvals cover a date range or a number of cycles. Treatment past either limit is unauthorized.
- Urgent starts. Treatment often cannot wait. The practice needs a policy for expedited requests, and for documenting why care started before approval.
The prior authorization services page describes how Mednex supports tracking and submission, and the prior authorization explainer covers basics. Authorization status should be checked before each cycle and again when the claim is built, since a prior approval does not guarantee payment.
Clinical trial billing
Clinical trials add a second payer: the sponsor. The core task is separating routine care costs, which may be billed to insurance, from items that are provided by or paid for under the trial. A coverage analysis, usually prepared with the study budget, maps each protocol service to the right payer. Billing staff then need a billing grid that follows the protocol schedule.
For Medicare, the clinical trial policy (National Coverage Determination 310.1) covers routine costs in qualifying trials. Medicare billing guidance from its contractors describes claim elements such as modifier Q1 for routine services and Q0 for investigational services, the diagnosis code Z00.6 on clinical trial claims, and an eight digit clinical trial identifier number (the NCT number) for certain study types. The contractor page reviewed for this article describes the institutional claim form, so professional claim placement should be confirmed with your Medicare Administrative Contractor. Commercial plans have their own rules and some require advance approval for trial participation.
Common clinical trial errors include billing a sponsor-paid service to insurance, missing the identifier on claims, enrolling a patient mid-cycle without updating the billing flag, and billing from the protocol schedule instead of the services performed. The practice’s research office usually owns the budget and the grid, and billing needs a direct channel to that office.
Radiation oncology basics
Radiation oncology billing is organized around the treatment course: consultation, simulation, treatment planning, dosimetry, treatment delivery, and treatment management. Treatment management is billed in blocks tied to the number of treatments, for example CPT 77427 for each group of five fractions, and cannot be billed more often than the payer allows. Setting matters. A freestanding center may bill globally or split professional and technical components, while a hospital-based department bills the technical side on a facility claim and the physician bills the professional side. The same component logic is explained on the radiology billing page.
Authorization for radiation therapy is commonly required, often by a radiation benefit manager, and may be tied to the technique, such as intensity-modulated or stereotactic treatment, and the number of fractions. The authorization should be checked against the plan of care and the actual delivered treatments. Brachytherapy, proton therapy, and special procedures carry additional code and payer rules. Confirm them with current CPT guidance and payer policy.
Common causes of oncology denials
| Denial pattern | Likely cause | Fix |
|---|---|---|
| Drug line denied, no authorization | Approval expired, regimen changed, wrong drug or dose on request | Verify dates and regimen; request retro review if permitted; update tracker |
| Wrong payment on drug line | Billing unit conversion error | Recalculate from the code’s unit definition; submit a corrected claim |
| Claim returned for JW or JZ | Modifier missing or discarded amount not in record | Add the modifier from the record; fix the nursing template |
| NDC rejection | Missing, wrong format, or not linked to the J-code | Check the package NDC against the crosswalk; resubmit |
| Administration code denied | Time not supported or wrong hierarchy | Compare to infusion record; recode; appeal only when time supports it |
| E/M bundled into treatment | No modifier 25 or note does not show a separate service | Add modifier only if documented |
| Trial service billed to insurance | Sponsor-paid item or missing trial identifiers | Check the billing grid; reverse if wrong |
| Drug denied because specialty pharmacy required | Payer policy on drug source | Follow the payer pathway; confirm the policy before ordering |
See the denial management page and the denial overview for how follow-up is handled.
Investigation and correction workflow
- Problem. Define the issue: a drug code with repeated denials, aging claims from one payer, or a gap between drug purchases and drug payments.
- Evidence to inspect. Pull the denial and remittance report, authorization log, infusion records for sample claims, drug purchase invoices, and the payer’s drug policy.
- Likely causes. Sort into authorization, unit conversion, code selection, modifier, documentation, pathway, or contract causes.
- Investigation steps. For each sample claim, compare the order, the dose given, the vial size, the units billed, and the payment. Check the payer policy for the date of service.
- Corrective action. Fix the cause at its source: a unit conversion table, a nursing field for discarded amount, an authorization alert before each cycle.
- Submission and follow-up. Correct and resubmit or appeal within each payer’s deadline, which varies. Follow up on a schedule, starting with the highest dollar claims.
- Prevention. Add pre-bill edits for units, NDC, and modifiers, and review new drug codes quarterly.
- Measurement. Track drug denial rate, dollar value of denied drug claims, and days in A/R for drug lines.
Hypothetical example: discarded drug and units
Hypothetical example. These numbers are round illustrations, not real prices or payer rules. A drug is supplied in a single-dose vial of 100 mg, and its J-code is defined per 10 mg. The vial equals 10 billing units. The patient’s dose is 80 mg, or 8 units. The remaining 20 mg, or 2 units, is discarded and documented in the record. Under the CMS approach for Medicare Part B, the claim lists one line of 8 units with no modifier and one line of 2 units with JW. If the billing team had entered 80 units by mistake, the payer would reject or overpay, and if it had entered 8 units with JZ, the discarded amount would be unpaid and the modifier would be wrong. If the dose had been 100 mg with nothing discarded, the claim would show 10 units with JZ. The point is the sequence: the nursing record supplies dose and waste, billing converts to units, and an edit checks that administered plus discarded does not exceed the container size.
How Mednex works with oncology practices
Mednex Group works through a defined workflow, confirmed in writing and dependent on your systems and payers.
- Verify eligibility and benefits, including the drug pathway for each payer.
- Track authorizations by regimen, with expiry dates and cycle counts.
- Review drug and administration charges against order, infusion, and inventory records, and send questions to the clinical team.
- Prepare and submit claims with units, NDC, and modifiers per payer rules.
- Post payments, compare drug payments to expected amounts where fee data is provided, and work denials and appeals.
- Follow up on aging A/R and report on denial reasons, aging by payer, and charge capture gaps.
Mednex and practice responsibilities
| Area | Mednex | Practice |
|---|---|---|
| Orders and clinical documentation | Flags gaps and asks questions | Writes orders, notes, and infusion records |
| Discarded drug records | Applies JW or JZ from the record | Captures container size and discarded amount |
| Authorizations | Submits, tracks, and reminds | Provides clinical rationale and joins peer-to-peer calls |
| Drug purchasing and pricing | Reports payment versus billed units | Manages distributors, inventory, and contracts |
| Clinical trials | Bills from the grid supplied | Maintains coverage analysis, budget, and the grid |
| Compliance | Follows agreed workflows | Owns compliance and final billing decisions |
Records and access needed
- EHR and practice management access, using the method agreed in writing
- Infusion and administration records, order sets, and the drug unit conversion table
- Authorization log and payer pathway or drug policy documents
- Drug purchase invoices or price data where payment comparison is in scope
- Clinical trial billing grids and coverage analyses, if applicable
- A/R aging, denial, and remittance reports, plus the payer list
Patient information moves only under a signed business associate agreement and through a secure workflow. Never send patient records through the website form.
Quality checks and exceptions
- Pre-bill edit that administered plus discarded units do not exceed the container size
- Check of billing units against the code definition for each drug
- Authorization match on drug, dates, and cycle count before submission
- Second review of high-dollar drug claims
- Separate queue for trial patients and for payers that use specialty pharmacy
- Quarterly review of new, changed, and retired drug codes
Exceptions include emergency starts before approval, drug shortages that force substitution, patients who change plans mid-course, and dose rounding policies. These are reviewed one at a time.
How progress is measured
Useful oncology measures include drug claim denial rate and dollar value, authorization-related denial rate, days in A/R for drug lines, A/R over 90 days, percentage of drug lines with correct JW or JZ, payment compared with expected allowed amount, and charge capture compared with infusion visits. See the clean claim rate and days in A/R guide, and the revenue cycle management page for broader reporting. Start from your own baseline and compare similar periods.
What cannot be promised
Mednex cannot guarantee reimbursement, authorization approvals, appeal outcomes, drug payment rates, or that a payer will accept a particular regimen. Payers set and change their own policies. Mednex does not make clinical decisions, give legal advice, or negotiate payer or distributor contracts.
Next steps
The Free Medical Billing Audit reviews a sample of recent claims, denial and rejection reasons, A/R aging by payer, and charge capture gaps, and ends with a written summary and walkthrough call. An oncology practice can ask that drug lines, administration codes, and authorization-related denials be part of the sample. Related pages include other specialty billing services, gastroenterology, and the contact page. Request the audit to see where drug and infusion claims are leaking.
Frequently asked questions
What do oncology billing services include?
They include eligibility and drug pathway checks, authorization tracking by regimen, review of drug and administration charges against infusion records, claim submission with units, NDC, and modifiers, payment posting, and denial and A/R follow-up. Clinical trial and radiation claims add their own steps. The practice stays responsible for orders, clinical notes, and drug purchasing. Mednex does not promise payer outcomes, and the scope is confirmed in writing before work begins. For oncology, a practical first review checks the highest-dollar denials and the share of drug lines without NDC or discard modifiers, since those errors carry the largest cost per claim.
How are chemotherapy administration codes chosen?
They follow a CPT hierarchy. In a physician office, the initial service is the one that best describes the reason for the encounter, and chemotherapy administration generally outranks therapeutic infusion and hydration. Time must be documented, with an infusion longer than 15 minutes for an initial hour and more than 30 minutes beyond it for an added hour. The infusion record must show start and stop times and access. Hospital-owned or provider-based practices should confirm which claim form applies to each service before coding. Because this hierarchy is easy to misapply when several services happen on the same day, many practices use a template that lists each service in order of the hierarchy and the time each requires.
What are the JW and JZ modifiers?
For Medicare Part B drugs in single-dose containers, JW reports the amount of drug discarded and JZ reports that none was discarded. The claim shows administered units on one line without a modifier and discarded units on a JW line, or full units with JZ. Multiple-dose containers are excluded, overfill is not payable, and the discarded amount must be in the patient record. Check other payers separately. Ask for the form and policy name in writing, since the rules for each payer are not identical. Hypothetical example: a 100 unit vial is opened and 90 units are given. The claim shows 90 administered units, and 10 discarded units with JW, so the payer sees the whole vial accounted for.
Why are oncology drug claims denied or underpaid?
Frequent causes are an expired or mismatched authorization, billing units converted incorrectly from the dose, a retired or wrong drug code, a missing NDC, and missing JW or JZ. Underpayment can also come from contract rates that fall below drug acquisition cost. Compare the order, dose, vial size, billed units, and remittance line by line to find which cause applies. Dollar value matters here, so sort the denials by amount and start with the largest lines. A sensible review starts with the largest lines. One payment for a high-cost drug can exceed a month of smaller claims, so sort denials by dollars and not by count.
What is the difference between buy and bill and specialty pharmacy?
In buy and bill, the practice purchases the drug and bills the payer for the drug and its administration. With specialty pharmacy supply, a pharmacy dispenses the drug for the patient and the practice generally bills only administration. Payer rules, state restrictions, cash flow, and waste handling differ, so the pathway must be known per payer and drug before the order is placed. Ask the payer which pathway applies to each drug before ordering, and record the answer with the date. Many practices keep a payer-by-drug table showing which pathway applies, the approving person, and the date checked, which prevents ordering a drug the payer expects from a pharmacy.
Do oncology treatments need prior authorization every cycle?
It depends on the payer. Many approve a regimen for a date range or a number of cycles, and treatment beyond either limit is unauthorized. Regimen changes, dose changes, and added drugs can require an amended request. Check the approval before each cycle, track expiry dates, and set a process for urgent starts and for documenting why treatment began before approval. Expedited review is often available for urgent starts, so know each payer's process before it is needed. A treatment calendar showing each patient's authorized cycles, expiry date, and next visit lets staff request extensions before the date is missed, rather than after a claim is denied.
How is clinical trial billing handled for insurance?
The practice separates routine care, which insurance may cover, from services paid by the sponsor. A coverage analysis and a billing grid map each protocol service to the right payer. Medicare guidance describes modifiers Q1 and Q0, diagnosis code Z00.6, and a trial identifier on certain claims, and details vary by claim type and contractor. Confirm requirements with your Medicare contractor and each commercial plan. Keep the research office in the loop, since protocol changes can alter which services insurance may be billed. Billing grids need maintenance. When the protocol is amended, the research office should send the updated grid so the billing team stops billing services the sponsor now covers.
Can a billing company bill radiation oncology services?
Yes, if it is set up for the practice's setting and software. Radiation billing follows the treatment course: planning, simulation, dosimetry, delivery, and management in blocks of treatments. Freestanding centers may bill global or split components, while hospital-based departments divide them between facility and professional claims. Authorization by technique and fraction count is common and should match what was delivered. Planning documents and delivered treatment records should match the authorization before the claim is sent. Confirm the software too. Radiation systems and treatment management records differ from infusion workflows, so ask what exports are available before assuming the billing team can reconcile treatments to claims.
How is pricing structured for oncology billing services?
Pricing depends on claim volume, number of providers and payers, and which tasks are in scope, such as authorizations, drug payment comparison, trial billing, or old A/R work. Mednex does not publish rates on this page. Ask any billing company for the pricing model in writing, including how drug revenue is treated and what costs extra, and compare quotes on the same scope. Compare quotes on the same scope so the numbers mean the same thing. Ask also how the company handles drug payments that fall below acquisition cost, whether it reports them, and who decides on an appeal. Those terms matter more than the headline fee.
Sources
Payer rules vary by payer, plan, state and contract. Check the current policy before acting.